A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Clinical trial NCT05427396 · TERMINATED

Trial details

NCT number: NCT05427396
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

Start date: 2022-07-28
Primary completion: 2024-01-15
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.